Prospective surveillance and management of cardiac toxicity and health in breast cancer survivors
Abstract
Breast cancer is commonly diagnosed in postmenopausal women, the majority of whom express 1 or more cardiovascular disease risk factors. Cardiovascular disease poses a significant competing risk for morbidity and mortality among nonmetastatic breast cancer survivors. Adjuvant systemic therapies may result in late‐cardiac toxicity decades after treatment completion. The cumulative incidence of treatment‐related cardiotoxic outcomes may be as high as 33% after some adjuvant breast cancer therapies. Breast cancer treatment–induced cardiotoxicity may manifest as cardiomyopathy, coronary ischemia, thromboembolism, arrhythmias and conduction abnormalities, and valvular and pericardial disease. Evidence indicates that preexisting cardiovascular conditions such as hypertension or left ventricular dysfunction may compound the adverse effects of cardiotoxic treatments. There are currently no published clinical practice guidelines that address ongoing cardiac surveillance for cardiotoxicity after breast cancer, and existing guidelines for monitoring and promoting cardiovascular health in older women are often not followed. The multidisciplinary prospective surveillance system proposed elsewhere in this supplement would allow for earlier detection of cardiotoxicity from treatment and may improve monitoring of cardiovascular health in the growing population of breast cancer survivors. Cancer 2012;118(8 suppl):. © 2012 American Cancer Society.Keywords
This publication has 50 references indexed in Scilit:
- The Influence of Comorbidities on Overall Survival Among Older Women Diagnosed With Breast CancerJNCI: Journal of the National Cancer Institute, 2011
- Effectiveness-Based Guidelines for the Prevention of Cardiovascular Disease in Women—2011 UpdateCirculation, 2011
- Heart Disease and Stroke Statistics—2011 UpdateCirculation, 2011
- Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trialsBMC Cancer, 2010
- Emerging Anticancer Therapeutic Targets and the Cardiovascular SystemCirculation Research, 2010
- General Cardiovascular Risk Profile for Use in Primary CareCirculation, 2008
- Prevention of High-Dose Chemotherapy–Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme InhibitionCirculation, 2006
- Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose ChemotherapyCirculation, 2004
- Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapyJACC, 2000
- Noncancer Deaths in White Adult Cancer PatientsJNCI: Journal of the National Cancer Institute, 1993